Nervgen Pharma Corp.

NervGen Pharma Strengthens Leadership Team with Appointment of Keith Vendola as Chief Financial Officer

NervGen Pharma to Participate in the H.C. Wainwright "HCW@Home" Series and the 2026 Bloom Burton & Co. Healthcare Investor Conference

NervGen Pharma Announces Successful End-of-Phase 2 Meeting and FDA Alignment on RESTORE, a Phase 3 Registrational Study of NVG-291 for Chronic Tetraplegia

NervGen Pharma Reports Full Year 2025 Financial Results and Provides Business Updates

NervGen Pharma Announces Voluntary Delisting from TSX Venture Exchange